---
title: "Bayer's First-in-Class Stroke Drug Won China First. Its Lead Over BMS Is About a Year"
url: https://drugnews.com.tw/articles/2026-11-12-bayer-sunharbo-asundexian-stroke-factor-xi-china-first-milvexian-en.html
date: 2026-11-12
lang: en
category: "製藥巨頭系列"
tags: ["stroke","Bayer","Factor XI","anticoagulation","Bristol Myers Squibb"]
summary: "FDA approved Bayer's Sunharbo on Nov 9, two weeks after China. It cut ischemic stroke 26% without a significant rise in major bleeding and lists at $748.50 a month. BMS and J&J report milvexian stroke data by end-2026."
json: https://drugnews.com.tw/articles/2026-11-12-bayer-sunharbo-asundexian-stroke-factor-xi-china-first-milvexian-en.json
publisher: Drugnews｜藥時事 (https://drugnews.com.tw/)
---
## 三句看懂

- The FDA approved Bayer's Sunharbo (asundexian) on November 9, 2026 for secondary prevention after non-cardioembolic stroke or high-risk TIA; China approved it on October 26.
- OCEANIC-STROKE enrolled 12,327 patients: ischemic stroke 6.2% vs 8.4%, ISTH major bleeding 1.9% vs 1.7%; bleeding was higher in patients over 75 and in high-risk TIA.
- Bristol Myers Squibb said on October 29 that milvexian stroke data come before end-2026 and atrial fibrillation data in Q1 2027.

## 關鍵數字（附來源）

| 項目 | 數值 | 日期 | 來源 |
|---|---|---|---|
| FDA 核准 Sunharbo（asundexian）用於非心因性缺血性中風或高風險 TIA 後降低中風風險 | 2026-11-09 date | 2026-11-09 | BioPharma Dive 2026-11-09 |
| 中國藥監局核准 Sunharbo，全球首個獲准 Factor XIa 抑制劑 | 2026-10-26 date | 2026-10-26 | Bayer 2026-10-26 |
| OCEANIC-STROKE 隨機分派人數 | 12327 人 | 2026-11-09 | NeurologyLive 2026-11-09 |
| 缺血性中風發生率 Sunharbo 對安慰劑 | 6.2 vs 8.4 % | 2026-11-09 | NeurologyLive 2026-11-09 |
| 缺血性中風相對風險降幅 | 26 % | 2026-11-09 | NeurologyLive 2026-11-09 |
| ISTH 大出血 Sunharbo 對安慰劑 | 1.9 vs 1.7 % | 2026-11-09 | NeurologyLive 2026-11-09 |
| 75 歲以上 ISTH 大出血 | 2.6 vs 1.7 每 100 人年 | 2026-11-09 | Bayer／StockTitan 2026-11-09 |
| 高風險 TIA 分組 ISTH 大出血 | 2.9 vs 1.0 每 100 人年 | 2026-11-09 | Bayer／StockTitan 2026-11-09 |
| 失能性中風風險比 | 0.69 HR | 2026-11-07 | Tech Times 2026-11-07 |
| 中位治療期間 | 14.2 月 | 2026-11-09 | NeurologyLive 2026-11-09 |
| 一年需治療人數（NNT） | 53 人 | 2026-11-09 | STAT 2026-11-09 |
| Sunharbo 美國 30 天份標價 | 748.5 美元 | 2026-11-09 | BioPharma Dive 2026-11-09 |
| Xarelto 2026 上半年銷售 | 7.38 億歐元（年減 43%） | 2026-11-09 | BioPharma Dive 2026-11-09 |
| Xarelto 2026 第三季銷售年減 | 31 % | 2026-11-03 | Yahoo Finance 2026-11-03 |
| Nubeqa 2026 第三季銷售年增 | 58 % | 2026-11-03 | Yahoo Finance 2026-11-03 |
| LIBREXIA ACS 主要終點 milvexian 對安慰劑 | 5.4 vs 5.1 % | 2026-08-29 | ESC 2026-08-29 |
| LIBREXIA ACS 人數 | 14194 人 | 2026-08-29 | ESC 2026-08-29 |
| milvexian 中風二級預防三期數據公布時程 | 2026 年底前 時程 | 2026-10-29 | Motley Fool 2026-10-29 |
| milvexian 心房顫動三期數據時程 | 2027 年第一季 時程 | 2026-10-29 | Motley Fool 2026-10-29 |
| Leerink 估 milvexian 2032 年風險調整後銷售 | 25 億美元 | 2026-11-09 | BioPharma Dive 2026-11-09 |
| 諾華收購 Anthos 預付款 | 9.25 億美元 | 2025-02-11 | Novartis 2025-02-11 |
| CHANCE 雙抗血小板 90 天再中風率 對 阿斯匹靈 | 8.2 vs 11.7 % | 2013-07-04 | NEJM 2013-07-04 |
| 中國缺血性中風盛行人數（2021） | 2000 萬人以上 | 2026-10-26 | Bayer 2026-10-26 |
| 腦血管疾病台灣十大死因排名 | 4 名 | 2026-10-28 | 國民健康署 2026-10-28 |

Roughly one in ten people who survive a non-cardioembolic ischemic stroke have another one within a year. Most leave hospital on aspirin, clopidogrel or both, and that regimen has barely changed in a decade.

On November 9, the US Food and Drug Administration approved Bayer's Sunharbo (asundexian), the first Factor XIa inhibitor on the US market, as an add-on to antiplatelet therapy after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA). In its Phase 3 trial it cut ischemic stroke by 26% with no statistically significant rise in major bleeding.

The odd detail is where the first approval landed. China's National Medical Products Administration cleared the drug on October 26, two weeks before the FDA.

**Bayer's head start is worth about one year. Bristol Myers Squibb and Johnson & Johnson's milvexian should hit its primary endpoint in secondary stroke prevention when data arrive before the end of 2026, with an effect in the same range as Sunharbo. From 2027 this is a two-player market, and Bayer's edge will come from early prescriptions in China and among stroke neurologists, not from better data.**

That call is wrong if milvexian's stroke trial misses its primary endpoint, or if it shows a clearly larger risk reduction, for example 35% or more.

## China first is the rational order, not an accident

Bayer said on October 26 that the Chinese regulator approved Sunharbo after a priority review. The FDA followed on November 9. Japan and the European Union are still reviewing.

A German drugmaker winning its first approval in Beijing looks like a scheduling quirk. The patient numbers explain it.

Stroke is the leading cause of death and disability in China. Bayer cites ischemic stroke prevalence above 20 million in 2021, up 10% from 2010. In the US, about 795,000 people have a stroke each year, roughly a quarter of them repeat events.

A once-daily pill layered on top of cheap antiplatelets is a volume business. Every prescription Bayer writes in China first becomes real-world safety data in East Asian patients, and that is the most practical asset it can hold against a follow-on rival.

On its third-quarter call on November 3, management called the Chinese label "solid" while US label talks with the FDA were still under way, and warned that launch spending in both countries from the first quarter would weigh on pharma margins.

![Fig. 1｜Key dates for Factor XI drugs](https://drugnews.com.tw/assets/articles/bayer-sunharbo-asundexian-stroke-factor-xi-china-first-milvexian-en/figure-01.png)

*Bayer recovered from its 2023 atrial fibrillation failure through the stroke trial; milvexian's stroke data are due by end-2026.*

## A 26% cut is not the biggest number; the bleeding profile is the product

An old benchmark helps. The 2013 CHANCE trial in 5,170 Chinese patients with minor stroke found that clopidogrel plus aspirin cut 90-day recurrence to 8.2% from 11.7% on aspirin alone. That is a larger relative cut than Sunharbo's, but dual antiplatelet therapy raises bleeding, so guidelines limit it to a few weeks.

OCEANIC-STROKE enrolled 12,327 patients and added asundexian on top of single or dual antiplatelets. Over a median 14.2 months of treatment, ischemic stroke occurred in 6.2% versus 8.4% on placebo. ISTH major bleeding was 1.9% versus 1.7%, a difference that was not statistically significant.

The value is that patients can stay on it. Treating 53 people for a year prevents one recurrent stroke, and strokes that did happen were less severe; the hazard ratio for disabling stroke was 0.69.

The line most coverage skipped sits in the label's subgroup data. In patients over 75, major bleeding ran at 2.6 per 100 patient-years versus 1.7. In high-risk TIA it was 2.9 versus 1.0. Older patients are the core of stroke clinics, and prescribers will read that row first.

There is also no approved Factor XIa reversal agent, and the label requires holding the drug for at least 24 hours after thrombolysis. Emergency teams will need new protocols for a patient who strokes again while on Sunharbo.

![Fig. 2｜OCEANIC-STROKE main results](https://drugnews.com.tw/assets/articles/bayer-sunharbo-asundexian-stroke-factor-xi-china-first-milvexian-en/figure-02.png)

*Ischemic stroke fell clearly; the major bleeding gap was small. Subgroup data are in the text.*

## The atrial fibrillation failure draws the class boundary

Sunharbo's success has an expensive prequel. In November 2023, Bayer stopped OCEANIC-AF early because patients on asundexian had more strokes and systemic embolism than those on Eliquis (apixaban).

That failure erased Bayer's earlier hopes of peak sales above €5 billion. The new US label states that the drug is not approved for stroke prevention in atrial fibrillation.

Milvexian walked a similar road. The LIBREXIA ACS trial in 14,194 patients after acute coronary syndrome was stopped for futility in November 2025; full results at ESC in August showed 5.4% versus 5.1% on placebo for the primary endpoint.

Together the two failures define the class. Factor XI inhibition is lighter anticoagulation. It can slow clots that grow on diseased artery walls, which is why it adds benefit on top of antiplatelets after an atherosclerotic stroke. It cannot stop the large stasis clots that form in a fibrillating atrium; that still takes full Factor Xa inhibition with drugs such as Eliquis or Xarelto.

![Fig. 3｜Factor XIa and Factor Xa act at different points](https://drugnews.com.tw/assets/articles/bayer-sunharbo-asundexian-stroke-factor-xi-china-first-milvexian-en/figure-03.png)

*Factor XIa mainly amplifies clot growth; normal hemostasis relies more on downstream Factor Xa and thrombin.*

That also explains Novartis's route. It paid $925 million upfront for Anthos Therapeutics in 2025 to get abelacimab, an injected antibody aimed at atrial fibrillation patients judged unsuitable for oral anticoagulants, sidestepping a head-to-head fight with Eliquis.

## How the business changes: from cents a day to $748.50 a month

A Bayer spokesperson told BioPharma Dive that a 30-day supply of Sunharbo lists at $748.50, about $9,000 a year. Aspirin and clopidogrel have long been cheap generics.

On the trial numbers, drug spending works out to roughly $480,000 for each recurrent stroke prevented. Bayer argues the drug bends the long-term cost curve of stroke and says that message resonates with payers. Pharma chief Stefan Oelrich said in August that access could be the launch's limiting factor.

Bayer needs the math to work. Xarelto sales fell 43% in the first half of 2026 to €738 million and dropped another 31% in the third quarter as generics spread outside the US. Growth now rests on prostate cancer drug Nubeqa, about €1 billion in third-quarter sales, and kidney drug Kerendia, up 65% in the quarter.

Sunharbo is meant to be the third pillar. When full data came out in February, Bayer reaffirmed only "blockbuster potential," meaning annual sales above €1 billion, and declined to give a peak figure until it saw labels and pricing. One trader put the ceiling at €3 billion.

The selling model changes too. Xarelto was a mass-market atrial fibrillation drug sold to cardiologists and primary care doctors. Sunharbo starts with stroke neurologists, and US head Sebastian Guth said primary care becomes a bigger focus later. Bayer is building a neurology-facing sales force, which is exactly the cost milvexian will also have to pay.

## BMS reports by year-end. What a one-year lead buys

Bayer has said it has roughly a one-year lead over milvexian. On its October 29 call, Bristol Myers Squibb said Phase 3 data in secondary stroke prevention would come before year-end and atrial fibrillation results in the first quarter of 2027.

Development head Cristian Massacesi pointed to a roughly 30% reduction in symptomatic stroke in Phase 2 and said the randomization window was chosen to give the best efficacy. Leerink Partners this month modeled $2.5 billion in risk-adjusted 2032 milvexian sales while warning that both large trials could disappoint.

The case for a positive stroke readout is simple. The mechanism is the same as Sunharbo's. The population is the same: non-cardioembolic stroke on top of antiplatelets. The ACS failure came in coronary arteries, where potent antiplatelet therapy already leaves little room for Factor XI to add benefit.

The real swing factor is atrial fibrillation. If milvexian holds up against Eliquis in the first quarter of 2027, BMS and J&J win the large market Bayer lost, and the positions flip. If it fails again, Factor XI stays boxed into stroke clinics and the race becomes one of prescribing habits.

![Fig. 4｜Where the three Factor XI drugs stand](https://drugnews.com.tw/assets/articles/bayer-sunharbo-asundexian-stroke-factor-xi-china-first-milvexian-en/figure-04.png)

*Bayer is on the market, BMS and J&J report stroke data by year-end, and Novartis avoids the AF head-to-head.*

The risks cluster in three places: the bleeding signal in older and TIA patients, which could narrow use to younger patients with clear atherosclerosis if post-marketing reports rise; the missing reversal agent; and price, since an add-on drug in the US needs insurer coverage to sell, the bottleneck Oelrich himself named.

## Taiwan: reimbursement, not just approval, sets the clock

Cerebrovascular disease has long ranked fourth among causes of death in Taiwan, and the Health Promotion Administration repeated that figure around World Stroke Day in late October.

We found no public record of a Taiwan filing for Sunharbo. The usual path is a US or EU approval first, then review by the Taiwan FDA and pricing by the National Health Insurance Administration.

China going first matters here. Sunharbo will build a large East Asian user base, and Taiwanese neurologists will use those data in reimbursement reviews to answer two questions: how much older patients bleed, and how many strokes the price buys.

There is a second Taiwan thread on the Factor Xa side. Taiwan's Taho Pharmaceuticals, covered here on November 5, is fighting a US patent case over its Eliquis-related product Beqia. Unless milvexian overturns the AF picture in early 2027, long-term anticoagulation in atrial fibrillation stays with Eliquis, its generics and reformulations. Factor XI is taking the add-on market in stroke clinics, not the segment Taho is betting on.

How the insurer runs the numbers will decide whether Taiwanese patients get the drug in 2027 or wait for milvexian and a price fight.

This article is industry and company analysis, not investment or medical advice.

## References

1. Bayer's SUNHARBO (asundexian) 50 mg tablets, the first and only Factor XIa inhibitor approved in the U.S.｜Bayer／StockTitan｜2026-11-09｜https://www.stocktitan.net/news/BAYRY/bayer-s-sunharbo-asundexian-50-mg-tablets-the-first-and-only-factor-onpa40n72aki.html
2. Asundexian first Factor XIa inhibitor approved in China for stroke risk reduction after priority review｜Bayer｜2026-10-26｜https://www.bayer.com/media/en-us/asundexian-first-factor-xia-inhibitor-approved-in-china-for-stroke-risk-reduction-after-priority-review/
3. FDA Approves Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention｜NeurologyLive｜2026-11-09｜https://www.neurologylive.com/view/fda-approves-asundexian-treatment-secondary-stroke-prevention
4. Bayer's novel drug for stroke recurrence wins FDA approval｜STAT｜2026-11-09｜https://statnews.com/2026/11/09/cardiovascular-stroke-recurrence-bayer-drug-fda-approval
5. Bayer wins FDA nod for a new kind of blood thinner｜BioPharma Dive｜2026-11-09｜https://www.biopharmadive.com/news/bayer-sunharbo-asundexian-fda-approve-stroke-factor-xi/872837/
6. Bayer's Asundexian Cuts Recurrent Stroke Risk by 26% Without Added Bleeding, Wins China Approval｜Tech Times｜2026-11-07｜https://www.techtimes.com/articles/330236/20261107/bayers-asundexian-cuts-recurrent-stroke-risk-26-without-added-bleeding-wins-china-approval-fda.htm
7. Bayer AG (BAYRY) Q3 2026 Earnings Call Highlights｜Yahoo Finance｜2026-11-03｜https://finance.yahoo.com/healthcare/articles/bayer-ag-bayry-q3-2026-210537813.html
8. Bayer Hesitates to Raise Sales Forecast Despite Asundexian Breakthrough｜MarketScreener／Reuters｜2026-02-06｜https://www.marketscreener.com/news/bayer-hesitates-to-raise-sales-forecast-despite-asundexian-breakthrough-ce7e5ad9dc8ef122
9. Bristol-Myers Squibb (BMY) Q3 2026 Earnings Call Transcript｜The Motley Fool｜2026-10-29｜https://www.fool.com/earnings/call-transcripts/2026/10/29/bristol-myers-squibb-bmy-q3-2026-earnings-call-transcript/
10. Milvexian did not reduce cardiovascular events in the LIBREXIA ACS trial｜ESC｜2026-08-29｜https://www.escardio.org/news/press/press-releases/milvexian-did-not-reduce-cardiovascular-events-in-the-librexia-acs-trial/
11. Update on Phase 3 Librexia ACS Trial｜Bristol Myers Squibb｜2025-11-13｜https://news.bms.com/news/details/2025/Update-on-Phase-3-Librexia-ACS-Trial/default.aspx
12. Novartis to acquire Anthos Therapeutics for USD 925 million upfront｜Novartis｜2025-02-11｜https://www.novartis.com/news/media-releases/novartis-bolsters-late-stage-cardiovascular-pipeline-agreement-acquire-anthos-therapeutics-usd-925-million-upfront
13. Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE)｜New England Journal of Medicine｜2013-07-04｜https://www.nejm.org/doi/full/10.1056/NEJMoa1215340
14. Stroke prevention fact sheet｜Taiwan Ministry of Health and Welfare, Health Promotion Administration｜2026-10-28｜https://mohw.gov.tw/cp-16-88307-1.html
